the poor outcomes associated with BRAF mt mCRC. Although potential improvement in survival with FOLFOXIRI has been suggested, current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer (Version 4.2020) still do not give
Search Results
Andrew Trunk, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna
Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II, and Chi Lin
study of a large, contemporary national database of a general US population aimed to evaluate national practice patterns and outcomes of unresected nonmetastatic GC receiving CT alone versus CRT. Although challenging to assess with single- or multi
Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen
provide the convenience for self-medication at home; however, they increase the risks for nonadherence, drug interactions, and adverse drug events (ADEs), which may threaten therapeutic outcomes and patient safety. 2 Oral chemotherapy drugs are perceived
Matthew A. Gubens and Marianne Davies
to have much poorer outcomes with single-agent immunotherapy. PD-L1 Expression ≥50% In KEYNOTE-024, pembrolizumab more than doubled median overall survival (mOS) compared with chemotherapy for patients with PD-L1 expression ≥50%, improving mOS to 30
Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman
outcomes of hospitalized patients with cancer in terms of infection, mortality, length of stay, and toxicities. The risk of cancer death (from stomach, liver, lung cancers) has been noted to be significantly higher among those with a high fasting plasma
Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini
data addressing management of this rare malignancy, we used the National Cancer Database (NCDB) to assess survival outcomes according to stage and treatment strategy in patients with anal adenocarcinoma. We focused our investigation on a comparison of
Lauren Lapointe-Shaw, Hani Abushomar, Xi-Kuan Chen, Katerina Gapanenko, Chelsea Taylor, Monika K. Krzyzanowska, and Chaim M. Bell
measurement have been used to address this problem by clearly delineating best practices. 2 Although many improvement efforts have centered on the coordination of outpatient care services, there are few studies of in-hospital care processes and their outcomes
Emily J. Martin, Eric J. Roeland, Madison B. Sharp, Carolyn Revta, James D. Murphy, Katherine E. Fero, and Heidi N. Yeung
-center, retrospective study, we evaluated PCA use and associated clinical outcomes in patients admitted to the hospital with cancer-related pain, defined as acute or chronic physical pain attributed to cancer or its treatment. Methods Study Cohort All
Tami Borneman, Barbara F. Piper, Virginia Chih-Yi Sun, Marianna Koczywas, Gwen Uman, and Betty Ferrell
health care outcomes? JAMA 1999 ; 282 : 867 – 874 . 23. Allard P Maunsell E Labbe J Dorval M . Educational interventions to improve cancer pain control: a systematic review . J Palliat Med 2001 ; 4 : 191 – 203 . 24. Ferris FD
Alexandra K. Zaleta, Shauna McManus, Joanne S. Buzaglo, Eva Y. N. Yuen, Julie S. Olson, Melissa F. Miller, Karen Hurley, Lillie D. Shockney, Sara Goldberger, Mitch Golant, and Kevin Stein
Background: Despite growing recognition that patient preferences and values should inform cancer care, patients’ views continue to be under-represented. We developed a quantitative tool, Valued Outcomes in the Cancer Experience (VOICE), to measure